- Home
- MGN vs ENLV Comparison
MGN vs ENLV Comparison
Compare MGN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | ENLV |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 5.1M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MGN | ENLV |
|---|---|---|
| Price | $2.13 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.4K | ★ 1.8M |
| Earning Date | 11-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.19 |
| 52 Week High | $5.18 | $7.64 |
Technical Indicators
Market Signals| Indicator | MGN | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 18.95 |
| Support Level | $0.11 | N/A |
| Resistance Level | $2.19 | $1.26 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 7.58 | 3.24 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.